Month: August 2021
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 17, 2021 /PRNewswire/ — Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. The new partnership will initially focus on SH-111, an oncology drug designed…
Read More
Excerpt from the Press Release: The U.S. Food and Drug Administration is informing patients, health care providers, and manufacturers about cybersecurity vulnerabilities with a “real-time operating system (RTOS)” designed by QNX and owned by BlackBerry. These vulnerabilities may introduce risks for certain medical devices and drug manufacturing equipment. FDA is not aware of any confirmed adverse events related to these vulnerabilities. Manufacturers…
Read More
Excerpt from the Press Release: Subsidies, tax breaks and funding will keep momentum going in Canada’s promising biomanufacturing industry. Why weren’t we better prepared? The frantic search for gloves and masks, then ventilators and life-saving drugs, and then the scramble to ramp up testing, slow the deaths in long-term care and deploy vaccines — the…
Read More
Excerpt from the Press Release: BRISBANE, Calif. – August 10, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrento’s proprietary mRNA vaccine development program for COVID-19.…
Read More
Excerpt from the Press Release: WALTHAM, Mass., Aug. 10, 2021 /PRNewswire/ — CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries. Eligible rheumatology registry patients will contribute biological specimens that will be linked to longitudinal provider reported clinical and…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine. The goals of…
Read More
Excerpt from the Press Release: SAN DIEGO, August 10, 2021 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced positive preliminary findings from the single ascending dose (SAD) portion of a first-in-human Phase 1…
Read More
Excerpt from the Press Release: Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic’s lead COVID-19 vaccine candidate. Dyadic’s lead COVID-19 Vaccine, DYAI-100,…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Indapta Therapeutics, Inc., a biotechnology company developing and commercializing an NK (natural killer) cell therapy platform for the treatment of blood cancers and solid tumors, today announced the publication of new preclinical data in Blood Advances demonstrating Indapta’s proprietary allogeneic FcεRIγ-deficient G-NK cells in combination with an FDA-approved monoclonal antibody…
Read More